A New Classification System for Grading the Severity of Onychomycosis

Onychomycosis Severity Index

Caitlin Carney, MD; Antonella Tosti, MD; Ralph Daniel, MD; Richard Scher, MD; Phoebe Rich, MD; Jamie DeCoster, PhD; Boni Elewski, MD

Objective: To establish and validate a new system to define the severity of onychomycosis. The Onychomycosis Severity Index (OSI) score is obtained by multiplying the score for the area of involvement (range, 0-5) by the score for the proximity of disease to the matrix (range, 1-5). Ten points are added for the presence of a longitudinal streak or a patch (dermatophytoma) or for greater than 2 mm of subungual hyperkeratosis. Mild onychomycosis corresponds to a score of 1 through 5; moderate, 6 through 15; and severe, 16 through 35.

Design: Consensus conference.

Setting: Teleconference.

Participants: The consensus group included 5 dermatologists, 1 dermatology resident with an interest in nail disorders, and a statistician. The meetings were held by closed teleconference.

Main Outcome Measures: Index reliability.

Results: The reliability of the OSI system was assessed in 2 steps. The first assessment included 37 dermatologists who scored 8 photographs of onychomycosis after being taught how to use the OSI. The scoring system showed very high reliability (Cronbach's $\alpha=0.99$ and intraclass correlation coefficient [ICC]=0.95). The second assessment entailed evaluation of 49 nails by 3 dermatologists, including an expert in the OSI. This assessment was conducted at the University of Alabama at Birmingham and at the Oregon Dermatology and Research Center, Portland. The scoring system showed very high reliabilities at both sites (Cronbach's $\alpha=0.98$ and ICC=0.96 at the University of Alabama at Birmingham, and Cronbach's $\alpha=0.98$ and ICC=0.93 at the Oregon Dermatology and Research Center).

Conclusion: The OSI is a new, simple, objective, reproducible numeric system to grade the severity of onychomycosis.

Arch Dermatol. 2011;147(11):1277-1282
est in nail disorders, and a statistician (J.D.), who met by closed telephone and e-mail. A total of 6 teleconferences were held, each lasting approximately 90 minutes for a total of 9 hours.

The Psoriasis Area Severity Index was the model used by the group to develop a grading system. In selecting clinical features to assess, the group considered the biological progression of DSO. In DSO, infection first spreads from the skin to the distal free edge or the lateral nail folds. In early infection, the nail plate may appear normal, and the infection is limited to the stratum corneum of the nail bed and the hyponychium. Eventually, this often leads to thickening of the stratum corneum (subungual hyperkeratosis). Then the infection may progress proximally along the rete ridges, appearing as streaks. As the nail plate becomes involved, its color may change to yellow, brown, or gray. Then the subungual hyperkeratosis progresses and the nail plate lifts, causing onycholysis. Over time, the nail plate begins to crumble and may become thickened. In some cases, subungual hyperkeratosis is not a prominent feature; instead, patches, longitudinal streaks, or both are present, which are representative of dermatophytomas or fungal "abscesses." Therefore, in severe cases of DSO, there are 2 subtypes: the first has prominent subungual hyperkeratosis (measured from the nail bed to the nail plate), and the second has fungal patches and/or streaks. These may occur concomitantly. Several characteristics have been associated with a poor response to treatment and are summarized in Table 1.

The clinical features chosen for scoring in the Onychomycosis Severity Index (OSI) are the area of involvement, proximity of disease to the matrix, occurrence of dermatophytomas, and presence of subungual hyperkeratosis (≥2 mm). In addition to the onychomycosis severity criteria in the literature (Table 1), more than 100 clinical photographs of diseased nails were examined to select easily identifiable features that represent the burden of disease and the likelihood of a poor treatment response, which is defined as the likelihood of a cure, the treatment length, and the patient’s perception of the disease. The area of involvement and the proximity of disease to the matrix are easily quantifiable and are clear measures of severity. The presence of a dermatophytoma and subungual hyperkeratosis are critical features because they represent the localized fungal burden in the nail.

**DEFINITION OF FEATURES**

**Area of Involvement**

*Area of involvement* is defined as the percentage of affected onychomycotic nail. It is measured using the boundaries of the lateral nail folds, proximal nail fold, and distal nail groove. In cases of long-term onycholysis, assessing the area of involvement can be particularly challenging because the nail bed disappears as the distal portion of the nail bed becomes keratinized and dermatoglyphics are present. In these instances, the distal groove should be approximated. In other situations, the patient or physician has cut the affected nail, and the area of involvement must be approximated from the distal groove. Although it may be difficult to determine the exact percentage of involvement, it is easier to determine a range of involvement by using a scale. One point is given if the disease involves 1% to 10% of the nail, 2 points for 11% to 25%, 3 points for 26% to 50%, 4 points for 51% to 75%, and 5 points for 76% or more of the nail. No points are awarded if no involvement is noted, and the nail is considered clinically cured. Involvement of 1% to 10% may occasionally indicate a “cure” if mycological analysis results are negative for fungus.

**Proximity of Disease to Matrix**

The nail is divided transversely into quarters starting distally and extending proximally. As the leading edge of disease moves proximally, it is given a score of 1 through 4 depending on which quarter the leading edge extends to. If the proximal edge is in the distal quarter of the nail, a score of 1 is awarded; if it extends to the first half of the nail, a score of 2; the third quarter, a score of 3; and the proximal quarter, a score of 4. A score of 5 is assigned only if there is definitive matrix infection that includes lunula involvement or disappearance of the leading edge under the proximal nail fold (Figure 1). We believe that the proximity of infection to the nail matrix is a very important prognostic factor and is a critical component of the OSI. Matrix involvement is an indicator of a poor prognosis and merits a separate score.

The proximity of infection to the nail matrix becomes especially significant when only lateral disease is present. In some instances, lateral disease extending to the lunula may make up only 10% of the nail surface and would be scored as only 1 if proximity to the matrix were not taken in account. Using this measure of severity, the score becomes 5.

---

**Table 1. Poor Prognostic Factors**

<table>
<thead>
<tr>
<th>Poor Prognostic Factor</th>
<th>Nail Characteristic</th>
<th>Organism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunosuppression</td>
<td>Subungual hyperkeratosis ≥2 mm</td>
<td>Nondermatophyte molds</td>
</tr>
<tr>
<td>Poor peripheral circulation</td>
<td>Significant lateral disease</td>
<td>Yeasts</td>
</tr>
<tr>
<td>Poorly controlled diabetes mellitus</td>
<td>Dermatophytoma (streak or patch) &gt;50% involvement</td>
<td>Mixed bacterial/fungal infections</td>
</tr>
<tr>
<td></td>
<td>Slow rate of nail growth</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe onycholysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total dystrophic onychomycosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Matrix involvement</td>
<td></td>
</tr>
</tbody>
</table>
Longitudinal Streaking or Patch (Dermatophytoma)

A longitudinal streak is often near the lateral nail fold. Caution must be exercised not to confuse streaks with onycholysis; consequently, we defined the **longitudinal streak** as extending from the free edge of the nail to the proximal edge of the nail. Dermatophytomas represent collections of fungal hyphae on histological examination, reminiscent of an aspergilloma. Penetration of antifungal drugs into dermatophytomas is considered limited. One study found that patients with a dermatophytoma were less likely to reach mycological cure when treated with oral terbinafine hydrochloride. A dermatophytoma may exist as a yellow, white, or orange longitudinal streak or as a white or yellow round patch. When evaluating a patch, the area must not be contiguous with the free edge of the nail, and a patch is not to be confused with onycholysis (Figure 2A and B). The presence of a patch or longitudinal streak is graded with 10 points, thereby pushing any nail with a dermatophytoma into the moderate or severe category depending on the area and length of involvement. More than 1 dermatophytoma may exist in the same nail; however, only 1 is graded, for a maximum of 10 points.

**Subungual Hyperkeratosis**

Subungal hyperkeratosis represents thickening of the stratum corneum in response to fungal infection, and the height is measured from the nail bed to the nail plate. This finding is considered a poor prognostic factor because antifungal therapy may have difficulty penetrating through the debris when it is greater than 2 mm thick, as stated in previous articles. The presence of subungal hyperkeratosis of greater than 2 mm is given a score of 10 points. If less than 2 mm of hyperkeratosis is present, no points are awarded. It is important that only the area of debris and not the nail plate itself is measured when assessing subungal hyperkeratosis.

**PERFORMING NAIL ASSESSMENT**

To assess the nail, the score for the area of involvement (range, 0-5) is multiplied by the score for the proximity of disease to the matrix, and 10 points are added for the presence of a dermatophytoma or subungal hyperkeratosis of greater than 2 mm. A cumulative score of 0 indicates cured; 1 through 5, mild onychomycosis; 6 through 15, moderate onychomycosis; and 16 through 35, severe onychomycosis.

**RELIABILITY ASSESSMENT**

A preliminary reproducibility assessment was performed by asking 15 dermatology residents, 1 dermatology research fellow, and 1 medical student to evaluate 8 onychomycotic nail photographs using the OSI. The photographs reviewed included

---

**Table 2. Onychomycosis Severity Index**

<table>
<thead>
<tr>
<th>Area of Involvement</th>
<th>Proximity of Disease to Matrix</th>
<th>Presence of Dermatophytoma or Subungal Hyperkeratosis &gt; 2 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affected Nail, %</td>
<td>No. of Points</td>
<td>No. of Points Present</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1-10</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>11-25</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>26-50</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>51-75</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>76-100</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amount of Involvement From Distal Edge</th>
<th>No. of Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1/4</td>
<td>1</td>
</tr>
<tr>
<td>1/4-1/2</td>
<td>2</td>
</tr>
<tr>
<td>1/2-3/4</td>
<td>3</td>
</tr>
<tr>
<td>&gt;3/4</td>
<td>4</td>
</tr>
<tr>
<td>Matrix involvement</td>
<td>5</td>
</tr>
</tbody>
</table>

**Note:** The Onychomycosis Severity Index is calculated as follows: the score for area of involvement is multiplied by the score for the proximity of disease to the matrix, and 10 points are added for the presence of a dermatophytoma or subungal hyperkeratosis of greater than 2 mm. A cumulative score of 0 indicates cured; 1 through 5, mild onychomycosis; 6 through 15, moderate onychomycosis; and 16 through 35, severe onychomycosis.
the photographs in Figure 3. The physicians and students recorded their scores on a grading sheet. Each answer was reviewed and compared with the answers from the consensus group. Although some variation occurred within actual numeric scores, almost all nail scores corresponded to the consensus group’s severity category. There were 15 errors among the 136 photographs graded by the 17 participants. All errors were related to misidentification of dermatophytomas, that is, nails were given an additional 10 points for the presence of a dermatophytoma by the participants when the consensus panel had not. This was the most difficult area for physicians to score because there was a low threshold to score a nail as having a dermatophytoma. Therefore, the aim was to keep the grading of a dermatophytoma as simple as possible by dividing the features into 2 categories: patch or longitudinal streak.

Two assessments were performed to show the reliability of the scoring system. Reliability was assessed using the Cronbach’s and the intraclass correlation coefficient (ICC). Values
for Cronbach \( \alpha \) greater than 0.7 are generally considered a marker of high reliability, and ICC values of greater than 0.9 generally indicate excellent correlation. The first assessment included 37 dermatologists who were asked to evaluate 8 photographs of onychomycotic nails after being taught how to use the OSI with images of different nails. A standard OSI scoring sheet was provided to each physician, and the same 8 photographs were projected onto a screen for evaluation. The scores were recorded on the OSI scoring sheet. The pictured nails represented a wide range of severity (individual nails had mean scores of 2.1, 2.8, 6.8, 7.4, 8.4, 15.4, 28.6, and 31.5). The scoring system showed very high reliability across all the nails (Cronbach \( \alpha = 0.99 \) and ICC = 0.95).

The second assessment entailed evaluation of 49 onychomycotic nails of patients by 3 people: an expert in the OSI scoring system (P.R. and B.E.) and 2 other dermatologists who were taught how to use the OSI. The expert and 2 randomly selected physicians were then asked to evaluate the same patient nail and record their score on the standard OSI scoring sheet. The physicians were blind to the scores assigned to the nail by the other evaluators. This assessment was conducted at 2 different sites: the University of Alabama at Birmingham (34 patients) and the Oregon Dermatology and Research Center (24 patients). The nails from both sites represented a wide range of severity (both sites had patients with mean severity scores ranging from 1 to 35; patients at the University of Alabama at Birmingham had a mean [SD] score of 13.6 [10.6], and patients at the Oregon Dermatology and Research Center had a mean score of 17.5 [10.3]). The scoring system showed very high reliabilities at both sites (Cronbach \( \alpha = 0.99 \) and ICC = 0.96 at the University of Alabama at Birmingham; Cronbach \( \alpha = 0.98 \) and ICC = 0.93 at the Oregon Dermatology and Research Center).

The OSI is a simple tool consisting of grading the percentage of nail plate involvement, proximity of infection to the matrix, degree of subungual hyperkeratosis, and presence of a dermatophytoma. The OSI showed high statistical reliability across dermatology experts in nail diseases and dermatologists who were not experts in nail disease performing as observers of photographed nails and live patient nails, indicating that it is easily learned and provides consistent results. In general, a nail with a low OSI score would be more likely to respond favorably to conventional therapy, whereas a nail with a high OSI score would be more difficult to treat. Likewise, moderate nail involvement scored as 6 would be easier to treat than moderate nail involvement scored as 15, and severe nail involvement scored as 16 would be easier to treat than severe nail involvement scored as 35.

Two previous scoring systems have been developed. The first system, by Sergeev et al., scored severity on the basis of the clinical form of onychomycosis, length of infection, degree of subungal hyperkeratosis, and rate of nail growth as predicted by age. Scores for each category were used in an equation that calculated a final numeric grade. The second system, by Baran et al., took into account 10 different clinical-, patient-, and organism-centered criteria that were weighted by prognostic implication. It did not define mild, moderate, and severe involvement, but instead was used to predict treatment response, and a higher score suggested a worse prognosis. However, neither of these systems has been validated.

Limitations of our study are that the OSI does not account for several published factors correlating with a poor prognosis, such as the patient's immune status, the organism, and the rate of nail growth. Some variation was seen between observers and, in most instances, involved scoring of the gray hyperpigmentation lining the proximal edge of the infection (Figure 2A). Whether this hyperpigmentation represents active infection or an inflammatory reaction to the infection is debatable because no study looking at this phenomenon currently exists, to our knowledge. The OSI was developed by analyzing photographs of diseased nails; however, it is intended to be used clinically. The interobserver variability in grading nail severity is likely due, in part, to evaluating a photograph of the nail.

By providing a standardized method for evaluating onychomycosis, the OSI provides an objective measurement of disease severity that may have a significant effect on future drug development and research studies. In clinical practice, this tool provides a quick and easy assessment of onychomycosis severity that may be tracked throughout a patient’s treatment course. It allows for quick documentation and may be used in place of photographs. Further evidence-based study is needed to properly correlate nail disease severity with response to treatment.

Accepted for Publication: July 20, 2011.

Correspondence: Boni Elewski, MD, Department of Dermatology, University of Alabama at Birmingham, Eye Foundation Hospital 414–Dermatology, 1530 Third Ave S, Birmingham, AL 35294 (beelewski@gmail.com).

Author Contributions: Drs Carney, Tosti, Rich, and Elewski had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Carney, Tosti, Daniel, Scher, Rich, and Elewski. Acquisition of data: Carney, Tosti, Daniel, Scher, Rich, and Elewski. Analysis and interpretation of data: Tosti, Daniel, Scher, Rich, and DeCoster, and Elewski. Drafting of the manuscript: Carney, Tosti, Scher, Rich, and Elewski. Critical revision of the manuscript for important intellectual content: Carney, Tosti, Daniel, Scher, Rich, and Elewski. Statistical analysis: Tosti, Rich, DeCoster, and Elewski. Administrative, technical, and material support: Carney. Study supervision: Elewski.

Financial Disclosure: Dr Tosti reports receiving honoraria from Polychem and Vichy Laboratories. Dr Daniel reports serving as a consultant to Medicis Pharmaceutical Corp; receiving honoraria from Medicis Pharmaceutical Corp, Medimetrics, and Nycomed; and receiving royalties from Elsevier Inc. Dr Scher reports serving as a consultant to and receiving honoraria from Allergan Inc, Anchor Pharmaceuticals, Celtic Pharma, Dow Pharmaceutical Sciences, Galderma, NanoBio Corporation, NitricBio Therapeutics, Stiefel Laboratories Inc (a GSK company), Talima Therapeutics Inc, and Topica Pharmaceuticals Inc. Dr Rich reports receiving honoraria from Centocor Ortho Biotech Inc, Merck & Co, Inc, Stiefel Laboratories Inc, and Talima Therapeutics; and receiving grants from Abbott Laboratories, Amgen Inc, Basilea Pharmaceutica, Celgene Corp, Celtic Pharma, Centocor Ortho Biotech Inc, Cipher Pharmaceuticals Inc, Cytotech, Dow Pharmaceutical Sciences Inc, Galderma, Genetech Inc, GlaxoSmithKline, Intendis Inc, Incyte, MedImmune, Mylotarg, Novartis, Pfizer, Prevail, Rhone-Poulenc Rorer, Takeda, and Teva Pharmaceutical Industries Ltd. Dr Elewski reports acting as a consultant to and receiving honoraria from Abbott Laboratories, Amgen Inc, Basilea Pharmaceutica, Celgene Corp, Celtic Pharma, Centocor Ortho Biotech Inc, Cipher Pharmaceuticals Inc, Cytotech, Dow Pharmaceutical Sciences Inc, Galderma, Genetech Inc, GlaxoSmithKline, Intendis Inc, Incyte, MedImmune, Mylotarg, Novartis, Pfizer, Prevail, Rhone-Poulenc Rorer, Takeda, and Teva Pharmaceutical Industries Ltd.
Inc, Merck & Co Inc, Merz Pharmaceuticals, Novartis, Novo Nordisk Inc, Novum Pharmaceut Research Services, Nycomed, Oregan Aesthetic Technologies, Pfizer Inc, Shionogi & Co Ltd, Stiefel Laboratories Inc, Talima Therapeutics Inc, Tolmar Inc, and Topica Pharmaceuticals Inc. Dr Elewski reports receiving honoraria from Intendis Inc and Merck & Co Inc and receiving grants from Abbott Laboratories, Amgen Inc, Centocor Ortho Biotech Inc, Dow Pharmaceuticals Inc, Merck & Co Inc, NitricBio Therapeutics, Novartis, and Pfizer Inc. None of these disclosures is relevant to the study reported in this article.

Role of the Sponsor: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: The Alabama Dermatology Society standardized the OSI scoring sheet.

REFERENCES

1. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997; 133(9):1172-1173.

Top-Accessed Article: Herbal Therapy in Dermatology


In this article, Bedi and Shenefelt present a comprehensive review of evidence-based uses of herbs in dermatology. Consumers are increasingly interested in treatment with “natural” remedies either because of the failure of conventional therapy or because of the belief that natural treatments lead to fewer adverse effects. By disease, the authors list the herbal treatments that have been studied in humans and animals, effective doses, hypothesized mechanism of action, and potential adverse effects. In a second section, they review cutaneous and systemic adverse effects, including fatalities, that can occur with the use of herbal treatments for dermatologic diseases as well as drug-herb interactions.

Unfortunately, Bedi and Shenefelt’s excellent review article cannot serve as an herbal treatment formulary because herbal treatments are considered to be dietary supplements, not drugs, by the Food and Drug Administration and therefore are not regulated or standardized. This lack of regulation puts the practitioner in the difficult position of knowing what may be effective without knowing where to send the patient to get it. In the analysis of various herbal products, not only has the active ingredient been found to be absent in some brands, but, in some cases, the product itself has been found to be adulterated with prescription medications or heavy metals. In the end, the article serves as a caveat against choosing natural over pharmaceutical treatment.

From August 2009 through August 2010, this article was viewed 2325 times on the Archives of Dermatology Web site.

Mary Ruth Buchness, MD

Contact Dr Buchness at Department of Dermatology, Columbia University, 560 Broadway, Ste 406, New York, NY 10012 (mimi_buchness@yahoo.com).